1. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012:
The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology.Developed
in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012; 14: 803-869. PMID: 22828712
2. Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology/American Heart Association
Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure). J Am Coll Cardiol 1995; 26: 1376-1398.
PMID: 7594057
3. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult:
Executive Summary A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines
(Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration With the
International Society for Heart and Lung Transplantation; Endorsed by the Heart Failure Society of America. Circulation 2001; 104:
2996-3007. PMID: 11739319
4. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure
in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing
Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the
American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm
Society. Circulation 2005; 112: e154-e235. PMID: 16160202
5. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and
Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task
Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation
2009; 119: e391-e479. PMID: 19324966
6. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Committee for Practice Guidelines (CPG). ESC guidelines for the diagnosis and
treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of
the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the
European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008; 10: 933-989. PMID: 18826876
7. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College
of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013; 128: e240-e327.
PMID:23741058
8. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management
of Heart Failure: A Report of the American College of Cardiology/ American Heart Association Task Force on Clinical Practice Guidelines
and the Heart Failure Society of America. Circulation 2017;136: e137-e161. PMID: 28455343
9. Guidelines for the diagnosis of heart failure. The Task Force on Heart Failure of the European Society of Cardiology. Eur Heart J 1995; 16:
741-751. PMID: 7588917
10. The treatment of heart failure. Task Force of the Working Group on Heart Failure of the European Society of Cardiology. Eur Heart J
1997; 18: 736-753. PMID: 9152644
11. Remme WJ, Swedberg K. Task Force for the Diagnosis and Treatment of Chronic Heart Failure, European Society of Cardiology.
Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001; 22: 1527-1560. PMID: 11492984
12. Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update
2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J
2005; 26: 1115-1140. PMID: 15901669
13. Nieminen MS, Böhm M, Cowie MR, et al. ESC Committe for Practice Guideline (CPG). Executive summary of the guidelines on the
diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur
Heart J 2005; 26: 384-416. PMID: 15681577
14. Ponikowski P, Voors AA, Anker SD, et al. Authors/Task Force Members. 2016 ESC Guidelines for the diagnosis and treatment of acute
and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of
Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37:
2129-2200. PMID: 27206819
15. Minds診療ガイドライン選定部会 監修．福井次矢，吉田雅博，山口直人 編．Minds診療ガイドライン作成の手引き 2007．医学書院2007.
16. Ponikowski P, Voors AA, Anker SD, et al. Authors/Task Force Members. 2016 ESC Guidelines for the diagnosis and treatment of acute
and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of
Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016;
18: 891-975. PMID: 27207191
17. Lindenfeld J, Albert NM, Boehmer JP, et al. Heart Failure Society of America. HFSA 2010 Comprehensive Heart Failure Practice
Guideline. J Card Fail 2010; 16: e1-e194. PMID: 20610207
18. Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J
Med 2006; 355: 251-259. PMID: 16855265
19. Vasan RS, Levy D. Defining diastolic heart failure: a call for standardized diagnostic criteria. Circulation 2000; 101: 2118-2121.
PMID: 10790356
20. Lee DS, Gona P, Vasan RS, et al. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection
fraction: insights from the framingham heart study of the nationalheart, lung, and blood institute. Circulation 2009; 119: 3070-3077.
PMID: 19506115
21. Punnoose LR, Givertz MM, Lewis EF, et al. Heart failure with recovered ejection fraction: a distinct clinical entity. J Card Fail 2011; 17:
527-532. PMID: 21703523
22. 厚生労働省．脳卒中、心臓病その他の循環器病に係る診療提供体制の在り方に関する検討会． 脳卒中、心臓病その他の循環器病に
係る診療提供体制の在り方について（平成29年7月）．
23. The criteria committee of the New York Heart Association. In: Nomenclature and Criteria for Diagnosis of Diseases of the Heart and
Great Vessels 9th edn. Little Brown & Co, 1994: 253-256.
24. Forrester JS, Diamond G, Chatterjee K, et al. Medical therapy of acute myocardial infarction by application of hemodynamic subsets
(second of two parts). N Engl J Med 1976; 295: 1404-1413. PMID:790194
25. Nohria A, Tsang SW, Fang JC, et al. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with
heart failure. J Am Coll Cardiol 2003; 41: 1797-1804. PMID:12767667
26. Mebazaa A, Gheorghiade M, Piña IL, et al. Practical recommendations for prehospital and early in-hospital management of patients
presenting with acute heart failure syndromes. Crit Care Med 2008; 36: S129-S139. PMID: 18158472
27. 厚生労働省．平成26年（2014）人口動態統計（確定数）の概況． http://www.mhlw.go.jp/toukei/saikin/hw/jinkou/kakutei14/index.html
28. 日本循環器学会．循環器疾患診療実態調査報告書（2016年度実施・公表）．http://www.j-circ.or.jp/jittai_chosa/jittai_chosa2015web.pdf
29. Okura Y, Ramadan MM, Ohno Y, et al. Impending epidemic: future projection of heart failure in Japan to the year 2055. Circ J 2008; 72:
489-491. PMID: 18296852
30. American Heart Association: Heart Disease and Stroke Statistics ̶ 2005 Update. Dallas, Tex; American Heart Association; 2005.
31. Vasan RS, Larson MG, Benjamin EJ, et al. Congestive heart failure in subjects with normal versus reduced left ventricular ejection
fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol 1999; 33: 1948-1955. PMID: 10362198
32. Tsutsui H, Tsuchihashi-Makaya M, Kinugawa S, et al. JCARE-CARD Investigators. Clinical characteristics and outcome of hospitalized
patients with heart failure in Japan. Circ J 2006; 70: 1617-1623. PMID: 17127810
33. Shiba N, Watanabe J, Shinozaki T, et al. CHART Investigators. Analysis of chronic heart failure registry in the Tohoku district: third year
follow-up. Circ J 2004; 68: 427-434. PMID: 15118283
34. Shiba N, Nochioka K, Miura M, et al. CHART-2 Investigators. Trend of westernization of etiology and clinical characteristics of heart
failure patients in Japan--first report from the CHART-2 study. Circ J2011; 75: 823-833. PMID: 21436596
35. Ushigome R, Sakata Y, Nochioka K, et al. CHART-2 Investigators. Temporal trends in clinical characteristics, management and
prognosis of patients with symptomatic heart failure in Japan -- report from the CHART Studies. Circ J 2015; 79: 2396-2407.
PMID: 26356834
36. Tsuchihashi-Makaya M, Hamaguchi S, Kinugawa S, et al. JCARECARD Investigators. Characteristics and outcomes of hospitalized
patients with heart failure and reduced vs preserved ejection fraction. Report from the Japanese Cardiac Registry of Heart Failure in
Cardiology (JCARE-CARD). Circ J 2009; 73: 1893-1900. PMID:19644216
37. Berry C. Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The survival of patients with heart failure with preserved
or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J 2012; 33: 1750-1757.
PMID: 21821849
38. Tsuji K, Sakata Y, Nochioka K, et al. CHART-2 Investigators. Characterization of heart failure patients with mid-range left ventricular
ejection fraction-a report from the CHART-2 Study. Eur J Heart Fail 2017; 19: 1258-1269. PMID: 28370829
39. Kawashiro N, Kasanuki H, Ogawa H, et al. Heart Institute of Japan-- Department of Cardiology (HIJC) Investigators. Clinical
characteristics and outcome of hospitalized patients with congestive heart failure: results of the HIJC-HF registry. Circ J 2008; 72: 2015-
2020. PMID: 18931450
40. Sato N, Kajimoto K, Keida T, et al. ATTEND Investigators. Clinical features and outcome in hospitalized heart failure in Japan (from the
ATTEND Registry). Circ J 2013; 77: 944-951. PMID: 23502987
41. Adams KF, Fonarow GC, Emerman CL, et al. ADHERE Scientific Advisory Committee and Investigators. Characteristics and outcomes
of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases
in the Acute Decompensated Heart Failure National Registry (ADHERE).Am Heart J 2005; 149: 209-216. PMID: 15846257
42. Nieminen MS, Brutsaert D, Dickstein K, et al. EuroHeart Survey Investigators. EuroHeart Failure Survey II (EHFS II): a survey on
hospitalized acute heart failure patients: description of population. Eur Heart J 2006; 27: 2725-2736. PMID: 17000631
43. Ho KK, Anderson KM, Kannel WB, et al. Survival after the onset of congestive heart failure in Framingham Heart Study subjects.
Circulation 1993; 88: 107-115. PMID: 8319323
44. Lloyd-Jones DM, Larson MG, Leip EP, et al. Framingham Heart Study. Lifetime risk for developing congestive heart failure: the
Framingham Heart Study. Circulation 2002; 106: 3068-3072. PMID:12473553
45. Bleumink GS, Knetsch AM, Sturkenboom MC, et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and
prognosis of heart failure The Rotterdam Study. Eur Heart J 2004;25: 1614-1619. PMID: 15351160
46. Kajimoto K, Minami Y, Sato N, et al. Investigators of the Acute Decompensated Heart Failure Syndromes (ATTEND) Registry. Gender
Differences in Anemia and Survival in Patients Hospitalized for Acute Decompensated Heart Failure With Preserved or Reduced
Ejection Fraction. Am J Cardiol 2017; 120: 435-442. PMID: 28583679
47. Sakata Y, Miyata S, Nochioka K, et al. Gender differences in clinical characteristics, treatment and long-term outcome in patients with
stage C/D heart failure in Japan. Report from the CHART-2 study.Circ J 2014; 78: 428-435. PMID: 24317114
48. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S.
Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334:1349-1355. PMID: 8614419
49. Shekelle PG, Rich MW, Morton SC, et al. Efficacy of angiotensin- converting enzyme inhibitors and beta-blockers in the management
of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am
Coll Cardiol 2003; 41: 1529-1538. PMID: 12742294
50. 日本心不全学会予防委員会．血中BNP やNT-proBNP値を用いた 心不全診療の留意点について．
51. McKee PA, Castelli WP, McNamara PM, et al. The natural history of congestive heart failure: the Framingham study. N Engl J Med 1971;
285: 1441-1446. PMID: 5122894
52. Wang CS, FitzGerald JM, Schulzer M, et al. Does this dyspneic patient in the emergency department have congestive heart failure?
JAMA 2005; 294: 1944-1956. PMID: 16234501
53. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N
Engl J Med 1984; 311: 819-823. PMID: 6382011
54. Nakata T, Nakajima K, Yamashina S, et al. A pooled analysis of multicenter cohort studies of (123)I-mIBG imaging of sympathetic
innervation for assessment of long-term prognosis in heart failure. JACC Cardiovasc Imaging 2013; 6: 772-784. PMID: 23845574
55. Rouleau JL, de Champlain J, Klein M, et al. Activation of neurohumoral systems in postinfarction left ventricular dysfunction. J Am
Coll Cardiol 1993; 22: 390-398. PMID: 8101532
56. Kawaguchi H, Kitabatake A. Renin-angiotensin system in failing heart. J Mol Cell Cardiol 1995; 27: 201-209. PMID: 7760344
57. Iwai N, Shimoike H, Kinoshita M. Cardiac renin-angiotensin system in the hypertrophied heart. Circulation 1995; 92: 2690-2696. PMID:
58. Mizuno Y, Yoshimura M, Yasue H, et al. Aldosterone production is activated in failing ventricle in humans. Circulation 2001; 103: 72-
77. PMID: 11136688
59. Young M, Fullerton M, Dilley R, et al. Mineralocorticoids, hypertension, and cardiac fibrosis. J Clin Invest 1994; 93: 2578-2583. PMID:
60. Struthers AD, MacDonald TM. Review of aldosterone- and angiotensin II-induced target organ damage and prevention. Cardiovasc Res
2004; 61: 663-670. PMID: 14985063
61. Yamamuro M, Yoshimura M, Nakayama M, et al. Direct effects of aldosterone on cardiomyocytes in the presence of normal and elevated
extracellular sodium. Endocrinology 2006; 147: 1314-1321. PMID:16373419
62. Qin W, Rudolph AE, Bond BR, et al. Transgenic model of aldosterone- driven cardiac hypertrophy and heart failure. Circ Res 2003; 93:
69-76. PMID: 12791709
63. Zannad F, Alla F, Dousset B, et al. Rales Investigators. Limitation of excessive extracellular matrix turnover may contribute to survival
benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study
(RALES). Circulation 2000; 102: 2700-2706. PMID: 11094035
64. Querejeta R, Varo N, López B, et al. Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in
hypertensive heart disease. Circulation 2000; 101: 1729-1735. PMID: 10758057
65. Cicoira M, Rossi A, Bonapace S, et al. Independent and additional prognostic value of aminoterminal propeptide of type III procollagen
circulating levels in patients with chronic heart failure. J Card Fail 2004; 10: 403-411. PMID: 15470651
66. Sudoh T, Kangawa K, Minamino N, et al. A new natriuretic peptide in porcine brain. Nature 1988; 332: 78-81. PMID: 2964562
67. Mukoyama M, Nakao K, Hosoda K, et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual
natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991; 87: 1402-1412. PMID: 1849149
68. Nakao K, Ogawa Y, Suga S, et al. Molecular biology and biochemistry of the natriuretic peptide system. I: Natriuretic peptides. J
Hypertens 1992; 10: 907-912. PMID: 1328371
69. Yoshimura M, Yasue H, Okumura K, et al. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients
with congestive heart failure. Circulation 1993; 87: 464-469. PMID: 8425293
70. Yasue H, Yoshimura M, Sumida H, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those
of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994; 90: 195-203. PMID: 8025996
71. Maisel AS, Nakao K, Ponikowski P, et al. Japanese-Western consensus meeting on biomarkers. Int Heart J 2011; 52: 253-265. PMID:
72. Harada M, Itoh H, Nakagawa O, et al. Significance of ventricular myocytes and nonmyocytes interaction during cardiocyte hypertrophy:
evidence for endothelin-1 as a paracrine hypertrophic factor from cardiac nonmyocytes. Circulation 1997; 96: 3737-3744. PMID:
73. Kuwahara K, Saito Y, Harada M, et al. Involvement of cardiotrophin- 1 in cardiac myocyte-nonmyocyte interactions during hypertrophy
of rat cardiac myocytes in vitro. Circulation 1999; 100: 1116- 1124. PMID: 10477538
74. Waeber B, Feihl F. Blood-pressure reduction with LCZ696. Lancet 2010; 375: 1228-1229. PMID: 20236699
75. Gu J, Noe A, Chandra P, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin
inhibitor (ARNi). J Clin Pharmacol 2010; 50: 401-414. PMID: 19934029
76. Yamamoto K, Burnett JC, Jougasaki M, et al. Superiority of brain na triuretic peptide as a hormonal marker of ventricular systolic and
diastolic dysfunction and ventricular hypertrophy. Hypertension 1996;28: 988-994. PMID: 8952587
77. Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart
failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction.
Circulation 1997; 96: 509-516. PMID: 9244219
78. Omland T, Persson A, Ng L, et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes.
Circulation 2002; 106: 2913-2918. PMID: 12460871
79. Anand IS, Fisher LD, Chiang YT, et al. Val-HeFT Investigators. Changes in brain natriuretic peptide and norepinephrine over time
and mortality and morbidity in the Valsartan Heart Failure Trial (Val- HeFT). Circulation 2003; 107: 1278-1283. PMID: 12628948
80. Suzuki S, Yoshimura M, Nakayama M, et al. Plasma level of B-type natriuretic peptide as a prognostic marker after acute myocardial
infarction: a long-term follow-up analysis. Circulation 2004; 110: 1387-1391. PMID: 15353502
81. Price JF, Thomas AK, Grenier M, et al. B-type natriuretic peptide predicts adverse cardiovascular events in pediatric outpatients with
chronic left ventricular systolic dysfunction. Circulation 2006; 114: 1063-1069. PMID: 16940194
82. Nishii M, Inomata T, Takehana H, et al. Prognostic utility of B-type natriuretic peptide assessment in stable low-risk outpatients with
nonischemic cardiomyopathy after decompensated heart failure. J Am Coll Cardiol 2008; 51: 2329-2335. PMID: 18549918
83. Seino Y, Ogawa A, Yamashita T, et al. Application of NT-proBNP and BNP measurements in cardiac care: a more discerning marker for
the detection and evaluation of heart failure. Eur J Heart Fail 2004; 6: 295-300. PMID: 14987579
84. Kawai M, Yoshimura M, Harada M, et al. Determination of the B-type natriuretic peptide level as a criterion for abnormalities in Japanese
individuals in routine clinical practice: the J-ABS Multi-Center Study (Japan Abnormal BNP Standard). Intern Med 2013; 52: 171-
177. PMID: 23318845
85. Sato Y, Yamada T, Taniguchi R, et al. Persistently increased serum concentrations of cardiac troponin t in patients with idiopathic dilated
cardiomyopathy are predictive of adverse outcomes. Circulation 2001; 103: 369-374. PMID: 11157687
86. Ishii J, Cui W, Kitagawa F, et al. Prognostic value of combination of cardiac troponin T and B-type natriuretic peptide after initiation of
treatment in patients with chronic heart failure. Clin Chem 2003; 49: 2020-2026. PMID: 14633873
87. Keller T, Zeller T, Peetz D, et al. Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med 2009; 361:
868-877. PMID: 19710485
88. Reichlin T, Hochholzer W, Bassetti S, et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J
Med 2009; 361: 858-867. PMID: 19710484
89. Latini R, Masson S, Anand IS, et al. Val-HeFT Investigators. Prognostic value of very low plasma concentrations of troponin T in patients
with stable chronic heart failure. Circulation 2007; 116: 1242- 1249. PMID: 17698733
90. Tsutamoto T, Kawahara C, Nishiyama K, et al. Prognostic role of highly sensitive cardiac troponin I in patients with systolic heart failure.
Am Heart J 2010; 159: 63-67. PMID: 20102868
91. Levine B, Kalman J, Mayer L, et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med
1990; 323: 236-241. PMID: 2195340
92. Ferrari R, Bachetti T, Confortini R, et al. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart
failure. Circulation 1995; 92: 1479-1486. PMID: 7664430
93. Tsutamoto T, Hisanaga T, Wada A, et al. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and
the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol
1998; 31: 391-398. PMID: 9462584
94. Anand IS, Latini R, Florea VG, et al. Val-HeFT Investigators. C-reactive protein in heart failure: prognostic value and the effect of valsartan.
Circulation 2005; 112: 1428-1434. PMID: 16129801
95. Pascual-Figal DA, Ordoñez-Llanos J, Tornel PL, et al. MUSIC Investigators. Soluble ST2 for predicting sudden cardiac death in patients
with chronic heart failure and left ventricular systolic dysfunction. JAm Coll Cardiol 2009; 54: 2174-2179. PMID: 19942089
96. Tsutamoto T, Wada A, Matsumoto T, et al. Relationship between tumor necrosis factor-alpha production and oxidative stress in the failing
hearts of patients with dilated cardiomyopathy. J Am Coll Cardiol 2001; 37: 2086-2092. PMID: 11419892
97. Tsutsui T, Tsutamoto T, Wada A, et al. Plasma oxidized low-density lipoprotein as a prognostic predictor in patients with chronic
congestive heart failure. J Am Coll Cardiol 2002; 39: 957-962. PMID: 11897436
98. Watanabe E, Matsuda N, Shiga T, et al. Significance of 8-hydroxy- 2’-deoxyguanosine levels in patients with idiopathic dilated
cardiomyopathy. J Card Fail 2006; 12: 527-532. PMID: 16952786
99. Anker SD, Doehner W, Rauchhaus M, et al. Uric acid and survival in chronic heart failure: validation and application in metabolic,
functional,and hemodynamic staging. Circulation 2003; 107: 1991-1997.PMID: 12707250
100. Sakai H, Tsutamoto T, Tsutsui T, et al. Serum level of uric acid, partly secreted from the failing heart, is a prognostic marker in patients
with congestive heart failure. Circ J 2006; 70: 1006-1011. PMID: 16864933
文献
(1～100)急性･慢性心不全診療ガイドライン（2017年改訂版）
Guidelines for Diagnosis and Treatment of Acute and Chronic Heart Failure
（JCS 2017/JHFS 2017）